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GLOSSARY OF ABBREVIATIONS 26 
§ MIMVS: minimally invasive video-assisted mitral valve surgery 27 
§ AF: atrial fibrillation 28 
§ MV: mitral valve 29 
§ SR: sinus rhythm 30 
§ TOE: trans-oesophageal echocardiography 31 
§ PVs: pulmonary veins 32 
§ LA: left atrium 33 
§ PV: pulmonary vein 34 
§ ECG: electrocardiography 35 
§ SD: standard deviation 36 
§ PM: pace maker 37 
§ NYHA: New York Heart Association functional class 38 
§ OAC: oral anticoagulation 39 
§ SVC: superior vena cava 40 
§ LIPV: left inferior pulmonary vein 41 
§ LSPV: left superior pulmonary vein 42 
§ RIPV: right inferior pulmonary vein 43 
§ RSPV: right superior pulmonary vein 44 
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§ IVC: inferior vena cava 45 
§ LV EF: left ventricular ejection fraction 46 
§ AP: antero-posterior 47 
§ SI: supero-inferior 48 
§ PAPs: systolic pulmonary artery pressure 49 
















Objectives: Interest in minimally invasive video-assisted mitral valve surgery (MIMVS) is rapidly 64 
growing. Data on concomitant atrial fibrillation (AF) ablation to MIMVS are still lacking. The 65 
present study investigates the long-term results of AF cryoablation concomitant to MIMVS. 66 
Methods: From October 2006 to September 2014, 68 patients with mitral valve (MV) disease (age 67 
65.9±11.1 years, 34/68 males, Euroscore log 5.4±4.5) and drug resistant AF underwent MIMVS via 68 
right mini-thoracotomy and concomitant left sided AF endocardial cryoablation (Cryoflex 69 
Medtronic, Minneapolis, MN, USA). Patients were independently followed by cardiological 70 
outpatients visits and underwent electrophysiological study when indicated. 71 
Results: Forty-four out of 68 patients (64.7%) underwent MV repair, 8/68 patients (11.8%) also 72 
received concomitant tricuspid valve surgery. One procedure was electively converted to full 73 
sternotomy (1.5%). Total clamp time was 97.6 ± 22.8 minutes. In March 2015, 60 patients were 74 
alive and completed the follow-up after a mean of 3.4±2.0 years following the procedure. Fourty 75 
eight patients (80%) presented sinus rhythm throughout the whole follow-up. Freedom from AF 76 
was respectively 96%, 87% and 72% at 1, 3 and 5 years. We recorded 2 pace-maker implants 77 
(3.3%). Three patients suffered symptomatic recurrences (2 atypical atrial flutter/1 atrial 78 
fibrillation) and underwent transcatheter ablation: all three patients remained in stable sinus rhythm 79 
for the remaining follow-up. 80 
Conclusions: Given the favourable long term sinus rhythm maintenance rates of concomitant 81 
Cryoablation, MIMVS can also be offered to symptomatic AF patients. AF transcatheter ablation 82 
may easily avoid further symptomatic recurrences. 83 





Interest in minimally invasive mitral valve (MV) surgery through a video-assisted mini-87 
thoracotomy approach (MIMVS) is rapidly growing since when was first introduced in the mid-88 
1990s [1]. A number of large studies have demonstrated the feasibility of performing MIMVS 89 
aiming to achieve similar safety and efficacy to conventional surgery with the added advantages of 90 
reduced trauma, improved cosmesis and shorter hospitalization [2,3]. 91 
Atrial fibrillation (AF) is the most common cardiac arrhythmia observed in clinical practice and 92 
confers an increased incidence of thromboembolic events and mortality [4]. A substantial increase 93 
in the incidence of AF has been reported in patients with indications for mitral valve surgery, and 94 
has also been demonstrated to be a profound risk factor for mortality [5]. The weight of this 95 
evidence has provided the impetus for the combination of surgical AF treatment and core cardiac 96 
surgical intervention, with the hope of synergistic improvements in both sinus rhythm (SR) 97 
maintenance and risk of morbidity and mortality [6, 7]. 98 
Concomitant surgical AF ablation and mitral valve surgery have proved to offer improved short- 99 
and mid-term SR maintenance compared to patients undergoing mitral valve surgery only. No 100 
differences were found between these two groups in terms of 30-day mortality, all-cause mortality, 101 
pacemaker implantation, stroke and thromboembolic events [8]. The advent of alternative energy 102 
sources has greatly simplified the original “cut and sew” technique to create transmural lines 103 
transforming surgical ablation into an easier, safer and faster procedure to be associated to MIMVS 104 
[9, 10]. Recently published guidelines have called for long-term follow-up studies on this topic [11-105 
14]. However data on follow-up after concomitant AF ablation to MIMVS are still missing. The 106 





Materials and methods 110 
is. From October 2006 to September 2014,out of 781 MIMVS,  the standard practice for MV 111 
disease in our Unit since October 2006, sixty-eight patients with concomitant drug resistant AF 112 
(13% paroxysmal, 87% persistent/long standing persistent) underwent video-assisted MIMVS via 113 
right mini-thoracotomy through the 4th intercostal space and concomitant left sided AF cryoablation 114 
(Cryoflex Medtronic, Minneapolis, MN, USA). Each patient in our study signed a written informed 115 
consent to undergo surgical or transcatheter procedures. Preoperative characteristics are 116 
summarized in Table 1. Patients that had already performed a cardiac surgical procedure or a 117 
previous transcatheter AF ablation were not included in this series. The analysis was conducted in 118 
an Academic medical center where patients accept to share their clinical data in an anonymous 119 
form. The study was observational and did not add treatment or modify conventional surgical 120 
procedure for the specific clinical indication. Surgical procedure. After a full preoperative work-up 121 
that included aorto-iliac angiography/CT scan, the most appropriate out of the following three 122 
MIMVS approaches was selected: direct aortic cannulation and endoaortic balloon occlusion 123 
(EndoDirect, Edwards Lifesciences, Irvine, CA); femoral arterial cannulation either with endoaortic 124 
ballon occlusion (EndoReturn, Edwards Lifesciences, Irvine, CA) or with transthoracic clamp 125 
(Chitwood Clamp, Scanlan International Inc, St Paul, MN). All patients underwent video-assisted 126 
right minithoracotomy through the 4th intercostal space (range 4-6 cm). Double lumen endotracheal 127 
ventilation, transoesophageal echo (TOE) and CO2 surgical field flooding were also used in all 128 
patients. Venous return was routinely obtained by double cannulation (jugular and femoral) and 129 
myocardial protection by cold crystalloid cardioplegia [15, 16].  130 
Concomitant left sided AF cryoablation (Argon based Cryomaze, Cryoflex Medtronic, Minneapolis, 131 
MN, USA) consisted of isolation of the pulmonary veins (PVs) and of the posterior left atrial (LA) 132 
wall between the veins by a “U” encircling cryolesion connected to the surgical paraseptal left atrial 133 
incision performed for mitral exposure, eventually creating the so-called “box lesion” (Figure 1). In 134 
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addition, a linear cryolesion (“mitral line”) was performed from the previously created “box lesion” 135 
to the mitral valve annulus to block conduction across the left atrial isthmus.  136 
Electrophysiology study and transcatheter AF ablation. Under conscious sedation, and guided by a 137 
3-dimensional electroanatomic mapping system (CARTO, Biosense Webster), the LA and PVs 138 
ostia were mapped measuring unipolar local voltage and detecting presence or not of PV isolation. 139 
In case of evidence of conduction gap between the PV and the atrium, antral pulmonary vein 140 
isolation was performed by radiofrequency ablation (Smartouch, Biosense Webster) aiming to 141 
complete PV isolation extending the surgical lesion set as demonstrated by circular mapping 142 
catheter (Lasso, Biosense Webster). 143 
Clinical follow-up and event definition. After discharge patients were followed by cardiological 144 
outpatient visits as for lone AF transcatheter ablation protocol [11] including clinical examination 145 
and ECG at 3, 6, 12 months and then yearly. Holter monitoring was performed at least once in all 146 
patients. In case of symptom recurrence between follow up visits patients were reassessed by 147 
clinical examination, ECG and Holter monitoring. Electrophysiological study and transcatheter AF 148 
ablation were performed when indicated. Study period was closed in March 2015, all patients with 149 
at least 6 months follow up were included and reassessed with clinical examination, ECG and 150 
transthoracic Echocardiography. 151 
Adverse events were classified according to the standardized definitions of the Society of Thoracic 152 
Surgeons/American Association of Thoracic Surgery/European Association of Cardiothoracic 153 
Surgery “Guidelines for Reporting Morbidity and Mortality in Cardiac Valvular Operations” and 154 
outcomes of AF cryoablation were reported following the HRS/EHRA/ECAS Expert Consensus 155 
Statement [11, 17]. A blanking period of three months was considered; following this interval any 156 
AF episode, persistent or paroxysmal, was registered as an event.  All events were also classified as 157 
early (occurring within 30 days from the procedure) or late (>31 days after the procedure). 158 
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Statistical analysis. Categorical variables are reported as counts and percentages, while continuous 159 
variables as means and standard deviations (SD). Correlations between parameters and study groups 160 
were tested in cross tabulation tables by means of the Pearson Chi-Square or Fisher’s Exact Test 161 
and by one-way ANOVA respectively for categorical and continuous variables. McNemar’s test 162 
was used on paired categorical variables. Kaplan Meier curves were computed to describe AF free 163 
survival over time. A two sided p-value <0.05 was considered statistically significant; all analyses 164 
were performed with SPSS 20.0 (IBM Corp., Armonk, NY, USA).. 165 
 166 
Results 167 
Forty-four out of 68 patients (64.7%) underwent mitral valve repair. By pathology, repair rates were 168 
32/37 (86.5%) degenerative, 11/15 (73.3%) functional, and 1/16 (0.6%) rheumatic. Eight patients 169 
(11.8%) received also concomitant tricuspid valve surgery (Table 2).  One procedure was electively 170 
converted to full sternotomy (1.5%) due to unexpected severe pleural adhesions and had an 171 
uneventful postoperative course. Total clamp time was 97.6±22.8 minutes. There was no reopening 172 
for any cause. 23/68 patients (33.8%) suffered AF relapses during hospitalization, 62 patients were 173 
discharged from the Unit in SR (91.2%). One in-hospital minor stroke was recorded (1/68, 1.5%); 174 
no patients required PM implantation in the acute phase. Early mortality was 1/68 (1.5%, due to 175 
respiratory complications following cardiac arrest resuscitated in the Ward). In March 2015 60 176 
patients completed the follow-up after a mean of 3.4±2.0 years following the procedure. Study flow 177 
chart following the procedure is depicted in Figure 2. In this time frame no patients required redo 178 
surgery; valve repair and replacement reported favourable results (no MR 43, 63.3%; <2+/4+ 25, 179 
36.7%). Three patients suffered from minor stroke (4.4%), while 1 patient (who relapsed on the 180 
second day after surgery with permanent AF) had a stroke (1.5%). Two (3.3%) patients required 181 
PM implantation during follow-up. Figure 3a illustrates echocardiographic parameters and 182 
functional class at baseline and at end of follow-up. Notably mean pulmonary artery pressure (from 183 
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46.0 to 36.1, p=0.006), antero-posterior left atrial diameter (from 54.5 to 49.2, p=0.012) and NYHA 184 
functional class (from 2.6 to 1,2, p<0.001) significantly decreased. Medications at baseline or 185 
discharge and end of follow-up are shown in Figure 3b. At 1-year follow-up 50% of patients 186 
discontinued amiodarone. Compared to discharge, significantly less patients were prescribed 187 
amiodarone at follow-up (56,3% vs. 18,8%, p<0.001) while  more patients assumed beta-blockers 188 
(9,4% vs 68,8%, p<0,001). Oral anticoagulants were discontinued in a significant proportion of 189 
patients (84,6% on OAC pre-surgery vs. 56,4% on OAC at follow-up, p<0.001); in particular, 13/60 190 
(21.7%) patients discontinued OAC at 1-year follow-up. At 1-year follow-up freedom from AF 191 
recurrences was 94.8%. Forty-eight patients (80%) presented SR throughout the whole follow up. 192 
Out of the 12 patients (20%) suffering relapses, 7 patients (58.3%) suffered paroxysmal episodes 193 
while 5 (41.7%) presented persistent AF (Figure 2). Seven patients (58.3%) relapsed as atypical 194 
atrial flutter while 5 (41.7%) as atrial fibrillation. Overall, three patients suffered symptomatic 195 
recurrences (2 atypical atrial flutter, 1 atrial fibrillation) and an electrophysiological study was 196 
indicated and performed in these patients (Figure 4). In two cases arrhythmia was sustained outside 197 
the lesion set while in one case a conduction gap was recorded. Following transcatheter ablation all 198 
three patients resulted in sinus rhythm for the remaining follow up. Freedom from AF relapses, 199 
stratified by AF type, is reported in Figure 5. Table 1 also describes preoperative characteristics of 200 
the patients population completing follow-up stratified by AF relapses at univariate analysis, 201 
highlighting that AF characteristics before the surgical ablation (if paroxysmal or persistent/long-202 
standing persistent) and NYHA class seem to significantly predict relapses.  203 
 204 
Discussion 205 
The main finding of the present study is that concomitant surgical video-assisted left sided AF 206 
cryoablation creating a box lesion plus a mitral line during MIMVS resulted in favourable long-207 
term sinus rhythm maintenance rates. Out of all, only three patients suffered symptomatic 208 
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recurrences, with ECG documentation of atypical atrial flutter in two cases and AF in one. 209 
Following transcatheter ablation, patients resulted in sinus rhythm for the remaining follow-up. 210 
Based on the present experience, therefore, in the remote case of symptomatic arrhythmia relapses, 211 
AF transcatheter ablation completing the surgical lesion set seems to easily avoid further 212 
recurrences.  213 
The cut-and-sew Cox-Maze III procedure has been the gold standard for surgical AF treatment and 214 
has proved to be effective at eliminating the arrhythmia [18]. In recent years the development of 215 
ablation technologies has dramatically changed the field of AF surgical ablation by the introduction 216 
of new techniques and energy sources [8,9,10], allowing the replacement of the surgical incisions 217 
with the linear ablation lines, transforming a technically complex procedure into an accessible and 218 
minimally invasive approach. Differently from paroxysmal AF, in which triggers from the 219 
pulmonary veins play an important role in the initiation of AF, in non-paroxysmal AF, atrial 220 
substrate modification is thought to be highly relevant [19]. This is especially true for patients with 221 
valvular heart disease, in which a dilated and remodeled atrium is present. In fact, previous studies 222 
have shown that mechanisms as the elongation and stretch of the atrial fibers and the presence of 223 
atrial fibrosis are crucial in the initiation and maintenance of AF in such a patients [20]. Therefore, 224 
procedures aiming to isolate the PVs and to permanently modify the atrial substrate with the 225 
creation of transmural linear lesions are indeed promising. 226 
The principal shortcomings of the use of minimal access techniques is that, due to potential 227 
suboptimal exposure, they may lead to an excess of simplification in the lesion set and potentially 228 
increase the possibility of conduction gaps. In this context, electrophysiological validation may 229 
permit electrical evaluation of the surgical ablation and allows to perform additional transcatheter 230 
ablation when necessary [21-23]. In fact, new hybrid approaches, combining minimally invasive 231 
surgical and percutaneous ablation are emerging [24].  232 
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Cryoablation during concomitant cardiac surgical procedures in sternotomy has appeared to be safe 233 
and effective [25]. Recently Gaita et al. reported that on patients with long-standing persistent AF 234 
and valvular heart disease, an hybrid approach including surgical cryoablation in sternotomy 235 
patients, consisting of pulmonary veins isolation and left atrial linear lesions combined with 236 
consequent transcatheter radiofrequency ablation was highly effective in maintaining very long-237 
term follow-up SR [24]. However, in this experience 21.2% of the patients needed transcatheter 238 
ablation touch-ups to eliminate conduction gaps and to complete atrial lines. In the present study 239 
safe and reproducible transmural lesions set in a bloodless surgical field, was achieved by an 240 
endocardial argon-based cooling cryoablation system with a flexible, easily adaptable to patient’s 241 
anatomy cryoprobe (−160°C for 120 seconds) without the need of consequent transcatheter touch-242 
ups in the vast majority of the cases. 243 
Another important issue regards the thromboembolic complications during follow up. Literature 244 
reports an annual stroke rate in surgically treated valvular patients varying from 0.8% to 3%. This 245 
thromboembolic risk is higher if AF is present [26,27]. In the present population, three patients 246 
experienced a minor stroke and one patient had a stroke during the follow-up, giving an overall 247 
annual rate of 1.7%. The maintenance of SR seems, therefore, to act as a protective factor against 248 
stroke, even in a population with surgical valvular heart disease in which the risk for 249 
thromboembolic events is inherently increased. 250 
Eventually, although surely influenced also by the concomitant MV surgery, minimally invasive AF 251 
cryoablation resulted to impact favourably the natural history of patients with MV disease and drug 252 
resistant symptomatic AF as shown by a significant reduction of NYHA class, and discontinuation 253 




Surgical cryoablation concomitant to MIMVS resulted to be highly effective in maintaining SR and 256 
reducing AF burden on long-term follow-up. Based on the present study population a minimally 257 
invasive approach can also be offered to symptomatic AF patients. In the remote case of 258 
symptomatic arrhythmia relapses, AF transcatheter ablation may easily avoid further recurrences. 259 
Study limitations 260 
The following limitations must be taken in account. First, this report is a observational study and 261 
may therefore be biased by patient selection by physician in charge. Second, the limited sample size 262 
may have influenced the statistical power of the analysis. Third the limited clinical events did not 263 
permit multivariate analysis to detect independent inference of the study parameters. Fourth, the 264 
follow-up of our study was mostly ECG-based. Being aware that a monitoring based on serial 24h 265 
ECG Holter tracings or, even better, implantable recorders would be more accurate, in a mostly 266 
persistent AF setting, consideration of any AF relapse, also those present only once during the 267 
follow up should limit event underestimation. Eventually, given that the surgical approach 268 
described is the standard and the only performed for this specific indication in our Center, no 269 
comparison group is available. 270 
 271 
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Figure Legends 355 
Central Picture (same as Fig. 2): Study flow chart. AF: atrial fibrillation; EP: 356 
electrophysiological.  357 
 358 
Figure 1. Anatomy of the left atrium following a para-septal atriotomy for exposure of the mitral 359 
valve using a left atrial lift system. Cryoablation lesion set performed in the study population 360 
connected to the left atriotomy thus creating a “box lesion”, plus the mitral cryoline. SVC, superior 361 
vena cava; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein; RSPV, right 362 
superior pulmonary vein; RIPV, right inferior pulmonary vein; IVC, inferior vena cava. (Modified 363 
from Illustrated techniques for performing the Cox-Maze IV procedure through a right mini-364 
thoracotomy, RJ Damiano Jr et al, ACS Vol 3, No 1) 365 
Figure 2. Study flow chart. AF: atrial fibrillation; EP: electrophysiological. 366 
Figure 3. (A) Echocardiographic parameters and functional class at baseline and end of follow-up 367 
within patients completing the 3.4 ±2.0 year follow-up. P value by Pearson Chi-Square/Fisher’s 368 
Exact Test or ANOVA. LV EF, left ventricular ejection fraction; AP, antero-posterior; SI, supero-369 
inferior; PAPs, systolic pulmonary artery pressure; NYHA, New York Heart Association functional 370 
class. (B) Medications at discharge and end of follow-up in patients completing the 3.4 ±2.0 year 371 
follow-up. P value by McNemar’s test. ACE-i, angiotensin-converting-enzyme inhibitor; OAC, oral 372 
anticoagulation. * indicates comparison between pre-surgery and follow-up. 373 
Figure 4. 3D electroanatomic reconstruction views: (A) Anteroposterior and leftlateral 3-D 374 
electroanatomic reconstruction view of the left atrium and pulmonary veins showing site of 375 
radiofrequency ablation (red dots) from the anterior portion of right superior pulmonary vein and 376 
the septal mitral isthmus and from the left inferior pulmonary vein and the lateral mitral isthmus. 377 
(B) Posteroanterior and right oblique (30°) 3-D electroanatomic reconstruction view of the left 378 
atrium and pulmonary veins showing absence of electrical activity on all the posterior wall (effect 379 
of surgical “box lesion”; upper part) and site of radiofrequency ablation (white dots) at the anterior 380 
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portion of the right superior pulmonary vein (site of conduction gap; lower part). (C) 381 
Anteroposterior and leftlateral 3-D electroanatomic reconstruction view of the left atrium and 382 
pulmonary veins showing the electrophysiological substrate and the site of radiofrequency ablation 383 
(red dots). 384 
Figure 5. Kaplan Meier curves for survival free from AF (persistent AF; persistent and/or 385 
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